---
layout: post
title: "Schedules of Controlled Substances: Placement of Lemborexant in Schedule IV"
date: 2026-02-05 19:08:40 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-04183
original_published: 2021-03-03 00:00:00 +0000
significance: 8.00
---

# Schedules of Controlled Substances: Placement of Lemborexant in Schedule IV

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 03, 2021 00:00 UTC
**Document Number:** 2021-04183

## Summary

This final rule adopts, without change, an interim final rule with request for comments published in the Federal Register on April 7, 2020, placing lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5- yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane- 1-carboxamide), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the Controlled Substances Act (CSA). With the issuance of this final rule, the Drug Enforcement Administration maintains lemborexant, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/03/2021-04183/schedules-of-controlled-substances-placement-of-lemborexant-in-schedule-iv)
- API: https://www.federalregister.gov/api/v1/documents/2021-04183

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
